← Back to the library
Published

Hexarelin

A synthetic GH secretagogue derived from GHRP-6; not FDA-approved, circulating as a research chemical, and prohibited in sport under WADA S2.

3
Primary sources
Not staged
Evidence stage
Jul 2026
Last reviewed

This page describes where Hexarelin has been studied, not what it will do for you. Findings here come largely from animal and cell models and do not establish safety or benefit in humans. Nothing here is medical advice, and Proven Panel sells nothing.

What it is

Hexarelin is a synthetic hexapeptide growth-hormone secretagogue, structurally derived from GHRP-6, that stimulates endogenous GH release via GH-secretagogue receptors.S1

Marketed as

Hexarelin is promoted for muscle growth, fat loss, recovery, and cardiovascular benefit. These are marketing claims, not established effects.S1

Regulatory status (US)

Hexarelin is not FDA-approved for human therapeutic use; its evidence base is predominantly preclinical with limited human data.S1 It circulates as a research chemical rather than a licensed medicine (see caveat on its compounding- framework status).S1

⚑ Provisional

Hexarelin's precise position within FDA's compounding framework should be confirmed against FDA's current listings; unlike GHRP-6/GHRP-2 it is not clearly in the active Category 2 table. S1

Around the world

Hexarelin is not an approved medicine; it is available internationally as a research-use-only substance rather than a marketed drug.S1

Evidence

Human data are limited; effects on the GH-IGF-1 axis have been observed in early studies, but hexarelin is not an approved therapy and its marketed body-composition and cardiovascular claims are not established.S1

Anti-doping

As a GH secretagogue, hexarelin (also called examorelin) is prohibited at all times under WADA S2.S2S3

Safety

As an unapproved research peptide, hexarelin has limited human safety data, and use falls outside any regulated finished-drug oversight; the general concerns for unapproved GH-axis peptides apply.S1

What's changing

The item to track is any clarification of hexarelin's status within FDA's compounding framework.S1

Sources

Every reference below is a primary source cited in this entry, drawn from the approved corpus.

  1. 01
  2. 02
  3. 03

Follow this compound

Get an email when FDA / WADA / ClinicalTrials moves on Hexarelin.

Follow this

The Panel Brief

What moved in supplement & peptide regulation this week. Free, cited, unsubscribe anytime.

You must be 18 or older to create an account.